Prostate cancer: 9. Treatment of advanced disease

CMAJ. Canadian Medical Association Journal

Volumn 160, Issue 2, 1999, Pages 225-232

  Gleave, Martin E ^a,d   Bruchovsky, Nick ^a   Moore, Malcolm J ^b   Venner, Peter ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; BUSERELIN; CYCLOPHOSPHAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; MITOXANTRONE; NILUTAMIDE; PARACETAMOL; PROSTATE SPECIFIC ANTIGEN; SURAMIN; THIAZIDE DIURETIC AGENT;

ARTICLE; BACKACHE; BONE SCINTISCANNING; DIARRHEA; DIET; GYNECOMASTIA; HUMAN; HYPERTENSION; LYMPH NODE; MALE; METASTASIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PROSTATE CANCER; PROSTATECTOMY;

EID: 0033604882     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 1. Bruchovsky N, Wilson JD. The conversion of testosterone to 5′-androstan-17′-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-7.
2. 2. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng II, et al. Characterisation of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7:23-36.
3. 3. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
4. 4. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-8.
5. 5. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281-6.
6. 6. Bruchovsky N. Androgens and antiandrogens. In: Holland JF, Frei E 3rd, Bast RC, Kufe DW, Morton DL, Weicselbaum RR, editors. Cancer medicine. 3rd ed. Philadelphia: Lea & Febiger; 1991. p. 884-96.
7. 7. Blackledge GR. High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology 1996;47(1A Suppl):44-7.
8. 8. Schellhammer PF, Sharifi R, Block N, Soloway MS, Venner PM, Patterson AM, et al. A controlled trial of bicalutamide vs flutamide, each in combination with LHRH analogue therapy, in patients with advanced prostate cancer. Cancer 1996;78:2164-9.
9. 9. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD. Low-dose cyproterone acetate plus mini-dose diethylstilbestrol - a protocol for reversible medical castration. Urology 1996;47:882-4.
10. 10. Crawford ED, Eisenberger MA, McLeod DG, Spalding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
11. 11. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-9.
12. 12. Gleave ME, Hsieh JT. Experimental animal models for prostate cancer. In: Lange P, Scher H, Ragavahn D, editors. Genitourinary oncology. New York: Lippincott; 1997. p. 367-78.
13. 13. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS. LHRH agonists in prostate cancer: elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 1993;72:1685-91.
14. 14. Miller JI, Ahmann FR, Drach GW, Emerson SS, Bottaccini MR. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 1992;147:956-61.
15. 15. Newling DWW, Denis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer: analysis of the criteria of evaluation used in the European Organisation for Research on Treatment of Cancer - Genitourinary Group Study 30853. Cancer 1993;72:3793-8.
16. 16. Huggins C, Scott WW. Bilateral adrenalectomy in prostate cancer. Ann Surg 1945;122:1031-41.
17. 17. Crawford ED, Eisenberger M, McLeod DG, Wilding G, Blumenstein BA. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients with stage D2 adenocarcinoma of the prostate: results of NCI intergroup study 0105 (SWOG and ECOG) [abstract]. Br J Urol 1997;80:278.
18. 18. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126-30.
19. 19. Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Intermittent androgen suppression for prostate cancer: rationale and clinical experience. Eur Urol 1998;34:37-41.
20. 20. Bolla M, Gonzalez MD, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
21. 21. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate vs deferred treatment for advanced prostate cancer: initial results of the MRC trial. Br J Urol 1997;79:235-46.
22. 22. Bruchovsky N, Goldenberg SL, Gleave ME, Rennie P, Akakura K, Sato N. Intermittent therapy for prostate cancer. Endocr Rel Cancer 1997;4:1-25.
23. 23. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective theapy with minimal side effects. J Urol 1995;154:1642-6.
24. 24. Siu LL, Moore MJ. Is there a role for chemotherapy in hormone refractory prostate cancer? Adv Oncol 1996;12:22-7.
25. 25. Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR Jr, Loening S, et al. Chemotherapy programs of the National Prostate Cancer Project (NPCP). Cancer 1980;45:1937-46.
26. 26. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-94.
27. 27. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MF, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone of symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-64.
28. 28. Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin S, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10:1754-61.
29. 29. Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994;12:2005-12.
30. 30. Hudes GR, Nathan FE, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96 hour paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-63.
31. 31. Myers C, Cooper M, Stein C, LaRocca R, Wlather MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-9.
32. 32. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 1993;85:611-21.
33. 33. Kelly WK, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher HI. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995;13:2208-13.